A phase II study of topotecan in patients with relapsed small-cell lung cancer.

abstract：BACKGROUND:Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of...

journal_title：Clinical lung cancer

authors： Lam VK,Tran HT,Banks KC,Lanman RB,Rinsurongkawong W,Peled N,Lewis J,Lee JJ,Roth J,Roarty EB,Swisher S,Talasaz A,Futreal PA,Papadimitrakopoulou V,Heymach JV,Zhang J

更新日期：2019-01-01 00:00:00

abstract：:The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...

journal_title：Clinical lung cancer

authors： Lee D,Heymach JV

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATI...

journal_title：Clinical lung cancer

authors： Aujollet N,Meyer M,Cailliod R,Combier F,Coignet Y,Campard S,Facy O,Bernard A,Girard C

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

journal_title：Clinical lung cancer

authors： Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 ...

journal_title：Clinical lung cancer

authors： Takenaka T,Takenoyama M,Toyozawa R,Inamasu E,Yoshida T,Toyokawa G,Shiraishi Y,Hirai F,Yamaguchi M,Seto T,Ichinose Y

更新日期：2015-01-01 00:00:00

abstract：:The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

journal_title：Clinical lung cancer

authors： Pacheco J,Bunn PA

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. PATIENTS AND METHODS:From February 2017 through Februa...

journal_title：Clinical lung cancer

authors： Gerber DE,Hamann HA,Chavez C,Dorsey O,Santini NO,Browning T,Ochoa CD,Adesina J,Natchimuthu VS,Steen E,Zhu H,Lee SJC

更新日期：2020-07-01 00:00:00

abstract：:This study was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease a...

journal_title：Clinical lung cancer

authors： Rizvi N,Hawkins MJ,Eisenberg PD,Yocum RC,Reich SD,Ligand L1069-20 Working Group.

更新日期：2001-02-01 00:00:00

abstract：:Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer. Insulin-like growth factor-binding protein 3 (IGFBP3) is also regulated by HIF1 but works in a completely different manner by modu...

journal_title：Clinical lung cancer

authors： Gharib TG,Chen G,Huang CC,Misek DE,Iannettoni MD,Hanash SM,Orringer MB,Beer DG

更新日期：2004-03-01 00:00:00

abstract：OBJECTIVE:Uncertainty exists regarding the optimal surveillance imaging schedule following definitive chemoradiation (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) with regards to both frequency and modality. We sought to document the clinical impact of frequent (at least every 4 months) surveillance ...

journal_title：Clinical lung cancer

authors： Ho QA,Harandi NK,Daly ME

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Human immunodeficiency virus (HIV)-infected individuals are at increased risk for primary lung cancer (LC). We wished to compare the clinicopathologic features and treatment outcome of HIV-LC patients with HIV-indeterminate LC patients. We also sought to compare behavioral characteristics and immunologic fea...

journal_title：Clinical lung cancer

authors： D'Jaen GA,Pantanowitz L,Bower M,Buskin S,Neil N,Greco EM,Cooley TP,Henry D,Stem J,Dezube BJ,Stebbing J,Aboulafia DM

更新日期：2010-11-01 00:00:00

abstract：:After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there has finally been a therapeutic advance. The combination of a platinum chemotherapy, etoposide, and an immune checkpoint inhibitor has yielded overall survival benefits in two successive phase 3 trials. Unfortunately, these trials o...

journal_title：Clinical lung cancer

authors： Friedlaender A,Liu SV,Passaro A,Metro G,Banna G,Addeo A

更新日期：2020-11-01 00:00:00

abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...

journal_title：Clinical lung cancer

authors： Matikas A,Kentepozidis N,Georgoulias V,Kotsakis A

更新日期：2016-11-01 00:00:00

abstract：INTRODUCTION:For patients with T1 or T2 N0 M0 small-cell lung cancer (SCLC), lobectomy followed by chemotherapy is the standard of care. However, because of its tendency for early dissemination, patients are often treated with concurrent chemo-radiation without surgery. This study was conducted to evaluate the utilizat...

journal_title：Clinical lung cancer

authors： Uprety D,Arjyal L,Vallatharasu Y,Bista A,Borgert A,Fitzsimmons AJ,Parsons BM

更新日期：2020-03-01 00:00:00

abstract：:Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib treatment in large, randomized monotherapy trials. In preclinical studies, gefitinib has shown additive and even supra-additive antitumo...

journal_title：Clinical lung cancer

authors： Hammond LA

更新日期：2003-09-01 00:00:00

abstract：BACKGROUND:Real-world data have suggested a detrimental effect of steroid use in patients with advanced non-small-cell lung cancer (NSCLC) receiving immunotherapy. However, previous studies included heterogeneous cohorts of patients receiving different lines of treatment with several immuno-oncology agents and various ...

journal_title：Clinical lung cancer

authors： Mountzios G,de Toma A,Economopoulou P,Friedlaender A,Banini M,Lo Russo G,Baxevanos P,Roila F,Banna GL,Christopoulou A,Jimenez B,Collazo-Lorduy A,Linardou H,Calles A,Galetta D,Addeo A,Camerini A,Pizzutilo P,Kosmidis P

更新日期：2020-10-14 00:00:00

abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...

journal_title：Clinical lung cancer

authors： Roof KS,Fidias P,Lynch TJ,Choi NC

更新日期：2003-05-01 00:00:00

abstract：PURPOSE:This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 15...

journal_title：Clinical lung cancer

authors： Wozniak AJ,Belzer K,Heilbrun LK,Kucuk O,Gadgeel S,Kalemkerian GP,Venkatramanamoorthy R,Kraut MJ

更新日期：2007-03-01 00:00:00

abstract：:Recent developments in the chemotherapy of advanced and metastatic non small-cell lung cancer have led to significant, albeit modest, improvements in survival and quality of life. The plethora of new agents with activity in this disease has led to questions as to how these drugs can best be added to existing regimens....

journal_title：Clinical lung cancer

authors： Edelman MJ,Gandara DR

更新日期：1999-11-01 00:00:00

abstract：:Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of ...

journal_title：Clinical lung cancer

authors： Tsao AS,Mehran R,Roth JA

更新日期：2009-01-01 00:00:00

abstract：:Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

journal_title：Clinical lung cancer

authors： Plunkett TA,Chrystal KF,Harper PG

更新日期：2003-07-01 00:00:00

abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...

journal_title：Clinical lung cancer

authors： Zenke Y,Yoh K,Matsumoto S,Umemura S,Niho S,Ohmatsu H,Goto K,Ohe Y

更新日期：2016-09-01 00:00:00

abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...

journal_title：Clinical lung cancer

authors： Holt GE,Disis ML

更新日期：2008-02-01 00:00:00

abstract：:The treatment of lung cancer--small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)--is a significant challenge in oncology. The best reported median survival remains near 1 year in advanced NSCLC despite several decades of steady improvement and extensive research with traditional chemotherapy drugs an...

journal_title：Clinical lung cancer

authors： Wakelee HA,Sikic BI

更新日期：2005-09-01 00:00:00

abstract：BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...

journal_title：Clinical lung cancer

authors： Qin A,Lusk E,Daignault-Newton S,Schneider BJ

更新日期：2019-07-01 00:00:00

abstract：BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...

journal_title：Clinical lung cancer

authors： Shiraishi Y,Kishimoto J,Tanaka K,Sugawara S,Daga H,Hirano K,Azuma K,Hataji O,Hayashi H,Tachihara M,Mitsudomi T,Seto T,Nakagawa K,Yamamoto N,Okamoto I

更新日期：2020-09-01 00:00:00

abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

journal_title：Clinical lung cancer

authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

更新日期：2001-08-01 00:00:00

abstract：:Lobectomy remains the standard procedure for early-stage non small-cell lung cancer (NSCLC). Advances in minimally invasive surgery allow lobectomy to be performed by videothoracoscopy (VATSLOBE). The objective of this study was to compare open thoracotomy (OPENLOBE) to VATSLOBE in the treatment of early-stage NSCLC. ...

journal_title：Clinical lung cancer

authors： Luketich JD,Meehan MA,Landreneau RJ,Christie NA,Close JM,Ferson PF,Keenan RJ,Belani CP

更新日期：2000-08-01 00:00:00

abstract：:Bevacizumab is the first molecularly targeted agent associated with improved outcomes in combination with chemotherapy in previously untreated patients with non-small-cell lung cancer (NSCLC). The addition of bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), to carboplatin and pacli...

journal_title：Clinical lung cancer

authors： Morgensztern D,Govindan R

更新日期：2008-03-01 00:00:00

abstract：UNLABELLED:Non–small-cell lung carcinoma (NSCLC) (n = 65) were analyzed for promoter methylation of RASSF1A, CDH13, MGMT, ESR1, and DAPK genes in matching lung tumors, normal lung tissue, and blood samples. Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC. Hypermethylation ...

journal_title：Clinical lung cancer

authors： Kontic M,Stojsic J,Jovanovic D,Bunjevacki V,Ognjanovic S,Kuriger J,Puumala S,Nelson HH

更新日期：2012-07-01 00:00:00